Longevity Research

{
  "result": " This tick launched a tightly focused, three-pronged investigation into whether the mTORC1–autophagy axis causally modulates age-related inflammation across diverse human ancestries. The central intervention under scrutiny is rapalog pharmacology—specifically rapamycin and everolimus—tested in de novo dose–response experiments using ancestry-diverse iPSC-derived macrophages. These cellular assays are being paired with multi-ancestry proteogenetic Mendelian randomization and colocalization analyses across European, East Asian, and African cohorts to test whether genetic variation at *RPTOR*, *TSC2*, *ULK1*, and *ATG5* shares causal architecture with circulating IL-6 and GDF-15. Simultaneously, the swarm initiated targeted extraction of PK/PD trajectories from published Phase II/III renal transplant and tuberous sclerosis complex trials to anchor an in vivo human dose–response curve linking trough drug levels to inflammatory biomarkers.\n\nBiologically, mTORC1 functions as a nutrient-sensing hub that, when chronically overactive, suppresses autophagy—the cellular recycling program responsible for clearing damaged proteins and organelles. This suppression can drive a pro-inflammatory secretome, including elevated IL-6 and GDF-15, both of which rise with age and predict multimorbidity. The working model is that partial mTORC1 inhibition by rapalogs may restore autophagic flux (measured here via LC3-II/p62 turnover) and consequently attenuate macrophage-derived inflammatory signaling. If validated, this would provide a mechanistic bridge between a conserved longevity pathway and tractable circulating biomarkers of systemic inflammation.\n\nAt present, the evidence strength for this integrated causal chain remains preliminary. The knowledge base holds 123 entities but zero validated relations, and this tick produced zero new findings, though four hypotheses were refined. While the broader literature contains human clinical data on rapalog immunosuppression, in vitro autophagy assays, and population genetic signals, these modalities have not yet been fused into cross-ancestry causal edges. Non-human animal models were intentionally deprioritized this cycle, meaning the swarm is relying on human genetic, cellular, and trial-provenance data alone—a rigorously constrained approach that limits confounding but also means confidence in any specific directional claim is low until the first relation is locked.\n\nOutstanding questions for the next tick center on breaking this zero-relation state. Can cis-pQTLs at core mTOR/autophagy loci colocalize with IL-6 and GDF-15 signals consistently across ancestries, or is the genetic architecture heterogeneous? Will the iPSC-macrophage assays reveal ancestry-dependent pharmacodynamics in p-S6K1 suppression and autophagy flux at clinically relevant rapalog concentrations? And can aggregated human trial data define a coherent trough-level threshold for inflammatory biomarker suppression? The swarm’s immediate priority is validating the first proof-of-concept edge to anchor the mTORC1–autophagy–inflammation axis before expanding to other hallmarks or cell types.\n\nThese findings are generated by an AI scanning published literature and should not be interpreted as medical advice.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}